Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (campath-1H)-based therapies

Cancer

Volumn 110, Issue 11, 2007, Pages 2478-2483

  Borthakur, Gautam ^a   Lin, E ^a   Faderl, Stefan ^a   Ferrajoli, Alessandra ^a   Wierda, William ^a   Giles, Francis ^a   Browning, Mary L ^a   Kantarjian, Hagop ^a   Keating, Michael ^a   O'Brien, Susan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Alemtuzumab; CD52 antigen; Cytomegalovirus reactivation; Lymphoproliferative disease

Indexed keywords

ALEMTUZUMAB; ANTIVIRUS AGENT; CD52 ANTIGEN; COTRIMOXAZOLE; FOSCARNET; GANCICLOVIR; IMMUNOGLOBULIN; RITUXIMAB; SERUM ALBUMIN; VALACICLOVIR; VALGANCICLOVIR;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME; VIRUS REACTIVATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, VIRAL; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; INCIDENCE; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; RISK FACTORS; SERUM ALBUMIN; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS ACTIVATION;

EID: 36448966375     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23031     Document Type: Article

References (20)

1. Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554-3561.
2. Lundin J, Kimby E, Bjorkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2002;100:768-773.
3. Slobedman B, Mocarski ES, Arvin AM, Mellins ED, Abendroth A. Latent cytomegalovirus down-regulates major histocompatibility complex Class II expression on myeloid progenitors. Blood. 2002;100:2867-2873.
4. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis. 2004;4:725-738.
5. Ferrajoli A, O'Brien SM, Cortes JE, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003;98:773-778.
6. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003;101:4267-4272.
7. Nguyen DD, Cao TM, Dugan K, et al. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Clin Lymphoma. 2002;3:105-110.
8. Laurenti L, Piccioni P, Cattani P et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica. 2004;89:1248-1252.
9. Faderl S, Thomas DA, O'Brien S, et al. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003;101:3413-3415.
10. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, Campath-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia. 2004;18:484-490.
11. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99:4357-4363.
12. Lamba R, Carrum G, Myers GD, et al. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with alemtuzumab. Bone Marrow Transplant. 2005;36:797-802.
13. Ng AP, Worth L, Chen L, et al. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. Haematologica. 2005;90:1672-1679.
14. Lin TS, Flinn IW, Lucas MS, et al. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia. 2005;19:1207-1210.
15. O'Brien SM, Kantarjian HM, Thomas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003;98:2657-2663.
16. van Dorp WT, Vlieger A, Jiwa NM, et al. The polymerase chain reaction, a sensitive and rapid technique for detecting cytomegalovirus infection after renal transplantation. Transplantation. 1992;54:661-664.
17. Eriksson BM, Wirgart BZ, Claesson K, et al. A prospective study of rapid methods of detecting cytomegalovirus in the blood of renal transplant recipients in relation to patient and graft survival. Clin Transplant. 1996;10:494-502.
18. Hadaya K, Wunderli W, Deffernez C, et al. Monitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay. J Clin Microbiol. 2003;41:3757-3764.
19. Van der Giessen M, van den Berg AP, van der Bij W, er al. Quantitative measurement of cytomegalovirus-specific IgG and IgM antibodies in relation to cytomegalovirus antigenaemia and disease activity in kidney recipients with an active cytomegalovirus infection. Clin Exp Immunol. 1990;80:56-61.
20. Becker BN, Becker YT, Heisey DM, et al. The impact of hypoalbuminemia in kidney-pancreas transplant recipients. Transplantation. 1999;68:72-75.